Novartis in hot water again over alleged kickbacks, revealing new DoJ probe related to Entresto

Max Gelman

Senior Editor

Novartis’ Entresto has proven a blockbuster drug since its approval in 2015, netting $924 million in sales this past quarter alone, representing a 46% gain …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis in hot water again over alleged kickbacks, revealing new DoJ probe related to Entresto

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA approves first drug to treat ultra-rare lipid storage disease

How AI can address ongoing challenges in the life sciences industry

No­var­tis in hot wa­ter again over al­leged kick­backs, re­veal­ing new DoJ probe re­lat­ed to En­tresto

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis in hot water again over alleged kickbacks, revealing new DoJ probe related to Entresto